drugset / Trial / NCT05312671
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Phase 2
Recruiting
63 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Timeline
- Start
- 2022-06-27
- Primary completion
- 2027-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |